Clinical Trial: Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
Study Status: Completed
Recruit Status: RECRUITING
Condition: Small Cell Lung Cancer (SCLC)
Study Type: INTERVENTIONAL
Official Title: A Randomized, Open-label, Phase 3 Study of Tarlatamab Compared With Standard of Care in Subjects With Relapsed Small Cell Lung Cancer After Platinum-based First-line Chemotherapy
Brief Summary:
The main objective is to compare the efficacy of tarlatamab with standard of care (SOC) on prolonging overall survival (OS).
Read more